Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staffs with a history of allergy.

Sumito Inoue¹⁾, Akira Igarashi¹⁾, Keita Morikane²⁾, Osamu Hachiya³⁾, Masafumi Watanabe¹⁾, Seiji Kakehata⁴⁾, Shinya Sato⁵⁾, and Yoshiyuki Ueno⁶⁾.

1) Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Japan

2) Division of Clinical Laboratory and Infection Control, Yamagata University Hospital, Japan

3) Division of Infection Control, Yamagata University Hospital, Japan

4) Department of Otolaryngology Head and Neck Surgery, Yamagata University Faculty of Medicine, Japan

5) Yamagata University Hospital, Yamagata University Faculty of Medicine, Japan

6) Department of Gastroenterology, Yamagata University Faculty of Medicine, Japan

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; SI has received lecture fees from Pfizer Japan Inc., and KYORIN Pharmaceutical Co.,Ltd. MW has received research grant and lecture fee from Pfizer Japan Inc. SS has received donation course for medical science and education from NISSIN PHARMACEUTICAL CO., LTD. no other relationships or activities that could appear to have influenced the submitted work.

Corresponding author: Sumito Inoue

Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan

2-2-2, Iida-Nishi, Yamagata, Japan, 990-9585

Email: sinoue@med.id.yamagata-u.ac.jp

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) vaccination is progressing globally. Several adverse reactions have been reported with vaccination against COVID-19. It is unknown whether adverse reactions to COVID-19 vaccination are severe in individuals with allergies. We administered the COVID-19 vaccine to the medical staff at Yamagata University Hospital from March to August 2021. Subsequently, we conducted an online questionnaire-based survey to investigate the presence of allergy and adverse reactions after vaccination and examined the association between allergy and adverse reactions after immunization.

Responses were collected from 1586 subjects after the first vaccination and 1306 subjects after the second administration of the BNT162b2 mRNA COVID-19 vaccine. Adverse reactions included injection site pain, injection site swelling, fever, fatigue or malaise, headache, chills, nausea, muscle pain outside the injection site, and arthralgia. The frequency and severity of most adverse reactions were higher after the second vaccination compared to the first. The frequency of some adverse reactions and their severity were higher, and the duration of symptoms was longer in subjects with allergies than in subjects without allergies. Although several participants visited the emergency room for treatment after the first and second vaccinations, nobody was diagnosed with anaphylaxis.

Given the serious consequence of COVID-19 and the reported high efficacy of this vaccine against this disease, we conclude that vaccination of allergic individuals is generally recommended.

Keywords

adverse reaction, allergy, BNT162b2 mRNA COVID-19 vaccine

Introduction

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) pandemic continues to spread worldwide, COVID-19 vaccination is one of the solutions to control it. BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is the first available mRNA vaccine in Japan in February 2021, which was initially administered to healthcare workers (1). Currently, several types of COVID-19 vaccines are available, and many people are being vaccinated (1, 2, 3). Although the efficacy of COVID-19 vaccination varies depending on the type of vaccine, the BNT162b2 has been reported to be 95% effective in preventing symptomatic COVID-19 infection in vaccinated individuals, indicating its high efficacy (1). Effective medications against COVID-19 include dexamethasone (4, 5), an antiviral agent remdesivir (6), and Janus kinase (JAK) inhibitor baricitinib (7), all of which are currently available in Japan for COVID-19 treatment. Although various other drugs are candidates for COVID-19 treatment, negative data on their efficacy, including those currently available, have been reported; hence, no reliable treatment is available (8).

Therefore, suppression of the COVID-19 pandemic by vaccination is considered important. However, there is a risk for adverse reactions to vaccination, and various adverse reactions have been reported with the COVID-19 vaccine (9). Adverse reactions such as pain at the vaccination site or fever are the main adverse reactions that have been reported. A particular problem with adverse reactions is allergic symptoms, and if anaphylaxis develops, there is a risk of life-threatening consequences (1-3). Since most people are receiving the COVID-19 vaccine for the first time, it is largely unknown whether the vaccination will cause adverse reactions, such as allergy or severe anaphylaxis. Particularly, it is difficult to determine whether individuals with allergies can receive the COVID-19 vaccine. However, to verify the safety of COVID-19 vaccines, individuals with a history of allergy to vaccine components were excluded from clinical trials. As a result, very few studies have examined the safety of COVID-19 vaccination in people with allergies.

At Yamagata University Hospital, Japan, BNT162b2 was administered to hospital staff and students. After vaccination, we conducted a questionnaire

survey to find out their allergy history and adverse reactions after immunization. By analyzing these data, we aimed to verify the safety of the COVID-19 vaccine in people with a history of allergy.

Materials and Methods

Study Design

The questionnaire survey was administered to the medical staff of Yamagata University Hospital and staff and medical students of Yamagata University Faculty of Medicine who received the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) from March 3, 2021 to August 27, 2021. After the first and second vaccination, a paper containing an internet link to the questionnaire was distributed. The questionnaire was designed using the free web-based Google Forms software. We asked the subjects their gender, age, occupation, history of allergy to food and/or medicine, history of allergic diseases, history of anaphylaxis, and history of adverse reactions to vaccination. As for adverse reactions after the immunization, the subjects were asked about injection site pain, injection site swelling, fever, fatigue or malaise, headache, chills, nausea, muscle pain outside the injection site, and arthralgia, as well as the timing of adverse reactions appearance and duration and degree of symptoms. The Institutional Ethics Committee of the Yamagata University Faculty of Medicine approved this study (approval number; 2021-130, approval date: June 29, 2021). The opt-out method was used to obtain informed consent, which is available on our website. Patients who refused to participate were excluded from the study. The individuals participated anonymously.

Statistical Analysis

All classified variables are presented as numbers and percentages. The differences between groups were evaluated using the chi-squared test. Significance was inferred for p values of <0.05 . Statistical analyses were performed using JMP version 11.0 software (SAS Institute, Cary, NC, USA).

Results

There were 1586 questionnaires returned from individuals who had received the first vaccination of BNT162b2, and 1306 questionnaires were returned from individuals who had received the second vaccination after approximately 3 weeks. Table 1 shows the profiles and allergy histories of individuals. Those who received the first vaccination were 522 (32.9%) male and 1064 (67.1%) female. By age group, 546 participants (34.4%) were in their 20s, 402 (25.3%) were in their 30s, 336 (21.2%) were in their 40s, 220 (13.9%) were in their 50s, and 82 (5.2%) were in their 60s or older. Of the participants, 193 (12.2%) had a history of allergy to food and/or medicine. There were 698 (44.0%) participants with allergic diseases, such as rhinitis and bronchial asthma, 27 (1.7%) had a history of anaphylaxis, and 90 (5.7%) had a history of adverse reactions after vaccination. The profiles were similar to those after the second vaccination.

The frequency of adverse reactions after first and second vaccinations is shown in Figure 1. Adverse reactions other than pain at the injection site occurred more frequently after the second vaccination. Table 2 summarizes the onset of adverse reactions, duration of symptoms, and severity of symptoms after the first and second vaccinations. In this study, adverse reactions after vaccination other than fever were defined as follows: moderate adverse reactions were those that interfered with daily life, and severe adverse reactions were those that required medical treatment. Moderate fever and severe fever were defined as a body temperature of 38°C or higher, and body temperature of 39°C or higher, respectively. For all adverse reactions, the frequency of symptoms lasting more than 2 days was high. The frequency of moderate or severe symptoms was also high.

Table 3 summarizes the frequency of adverse reactions by gender and age. The frequency of fatigue or malaise, headache, chills, nausea, and muscle pain outside the injection site after the first vaccination was significantly higher in females than in males. After the second vaccination, the frequency of fever, fatigue or malaise, headache, chills, nausea, muscle pain outside the injection site, and arthralgia was significantly higher in females than that in males. No adverse reactions occurred with a significantly higher incidence in males. In the

analysis by age, the frequency of injection site pain, injection site swelling, fever, and nausea after the first vaccination was significantly higher in younger people. The frequency of injection site pain, fever, fatigue or malaise, headache, chills, nausea, and muscle pain outside the injection site after the second vaccination was significantly higher in the younger age group.

Table 4 summarizes the frequency of adverse reactions by allergic status. Those who have a history of allergy to food and/or medicine had a significantly higher incidence of fatigue or malaise, headache, chills, nausea, and arthralgia after the first vaccination and a higher incidence of headache, nausea, muscle pain outside the injection site, and arthralgia after the second vaccination than those without a history of allergy to food and/or medicine. Those who have a history of allergic diseases, such as bronchial asthma and allergic rhinitis, had a significantly higher incidence of injection site pain, injection site swelling, fever, fatigue or malaise, headache, nausea, and arthralgia after the first vaccination, and a higher incidence of injection site swelling and nausea after the second vaccination than those without a history of allergic diseases. Those who have a history of anaphylaxis had a significantly higher incidence of fatigue or malaise after the first vaccination and a lower incidence of headache after the second vaccination than those without a history of anaphylaxis. Those who have a history of adverse reactions after vaccination had a significantly higher incidence of injection site swelling, fever, fatigue or malaise, headache, and chills after the first vaccination and a higher incidence of injection site pain and injection site swelling, nausea, and arthralgia after the second vaccination than those without a history of adverse reactions after vaccination.

Table 5 shows whether individuals with allergies continued to have adverse reactions after vaccination for a long period of time. The frequency of fatigue or malaise after the first and second vaccinations and headache and chills after the second vaccination, lasting more than two days, was significantly higher among those with a history of allergy to food and/or medicine than those without. The frequency of fever after the first vaccination and injection site pain after the second vaccination, lasting more than two days, was significantly higher among those with a history of allergy than those without. The frequency of adverse

reactions lasting more than 2 days after vaccination did not differ with the presence or absence of a history of anaphylaxis. The frequency of fatigue or malaise and headache after the second vaccination, lasting more than two days, was significantly higher among those with a history of adverse reactions after vaccination than those without.

Table 6 demonstrates whether the frequency of moderate to severe adverse reactions after vaccination differs, according to the presence or absence of allergy. Individuals with a history of allergy to food and/or medicine had significantly a higher incidence of moderate to severe arthralgia after the first vaccination and muscle pain outside the injection site after second vaccination than those without. The frequency of moderate to severe adverse reactions after vaccination did not differ with the presence or absence of a history of allergic diseases or anaphylaxis. Individuals with a history of adverse reactions after vaccination had a significantly higher incidence of moderate to severe fatigue or malaise after the first vaccination and injection site pain and chills after the second vaccination than those without. After the first and second vaccinations, a total of four subjects (one male and three females in their 20s to 40s) visited the emergency room for treatment, but none were diagnosed with anaphylaxis. One of them had a food allergy and allergic rhinitis while the other three had no allergy. No other life-threatening adverse reactions or deaths were reported.

Discussion

We administered the BNT162b2 to medical staff and investigated post-vaccination adverse reactions. The results showed that the frequency of adverse reactions after the COVID-19 vaccination was higher, the duration of symptoms was longer, and the symptoms were more severe after the second vaccination than after the first. Females and younger individuals experienced adverse reactions at a higher rate than males and the elderly, respectively. These results were consistent with previous reports (10). In our present analysis, we examined adverse reactions after COVID-19 vaccination in participants with allergies. Those who have a history of allergy to food and/or medicine, allergic diseases such as bronchial asthma or allergic rhinitis, a history of anaphylaxis or adverse reactions after vaccination had a significantly higher frequency of some adverse reactions compared to those without. Some adverse reactions showed a higher frequency of longer symptom duration after vaccination and a higher frequency of moderate or severe adverse reactions, but the differences were not outstandingly large. Additionally, no serious life-threatening allergic events were experienced after the BNT162b2 vaccination at our hospital.

In a previous report, the COVID-19 vaccination of hospital staff was performed, and the frequency of adverse reactions was examined according to the presence or absence of allergy (11). They found that subjects with a history of allergy had a significantly higher incidence of adverse reactions after vaccination than those without. They concluded that the BNT162b2 is less well tolerated in allergic individuals than in non-allergic participants, but the adverse reactions that occurred were mild and did not interfere with the successful completion of vaccination. Our results and conclusions are comparable, but our study is valuable since we not only investigated the presence or absence of allergy but also a detailed history of anaphylaxis and previous histories of adverse reactions to vaccination. Furthermore, our data are from the Japanese population. Therefore, we believe that our findings will be useful information for Japanese people who have a history of allergy to food and/or medicine, history of allergic diseases, history of anaphylaxis, and history of adverse reactions to vaccination.

There are several limitations to our study. The first limitation is that the survey

was an internet-based questionnaire, and symptoms and allergy history were self-reported. Particularly, it is unclear whether the diagnosis of allergic diseases is correct. Secondly, not many subjects had a history of anaphylaxis or adverse reactions to vaccinations; thus, the statistical reliability of the study may not be high. Thirdly, it is possible that some of the staff did not receive the vaccine because of a history of allergy. Therefore, it is possible that some people with a history of allergies may not have participated in this study. It is expected that large-scale and detailed data on adverse reactions to COVID-19 vaccination will be accumulated in the future, and the advantages and disadvantages of vaccination, especially for people with a history of allergy, will be verified.

In conclusion, although the tolerance of BNT162b2 was worse in individuals with allergies than those without, no serious adverse reactions such as anaphylaxis or death were observed. For those who are hesitant about COVID-19 vaccination because of allergy, data from a large adverse reaction study can be expected to be very helpful. We hope that the results of this study will be used to successfully complete the vaccination.

Acknowledgment

The authors would like to thank all the health care professionals involved in COVID-19 treatment at Yamagata University Hospital. The authors would like to thank Enago (www.enago.jp) for the English language review.

References

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383:2603-2615. doi: 10.1056/NEJMoa2034577.
2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384:403-416. doi: 10.1056/NEJMoa2035389.
3. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbald AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety

and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397:99-111. doi: 10.1016/S0140-6736(20)32661-1.

4. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*. 2021;384:693-704. doi: 10.1056/NEJMoa2021436.
5. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior GFS, Morais DC, Zung S, Machado FR, Azevedo LCP; COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA*. 2020;324:1307-1316. doi: 10.1001/jama.2020.17021.
6. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*.

2020;383:1813-1826. doi: 10.1056/NEJMoa2007764.

7. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med*. 2021;384:795-807. doi: 10.1056/NEJMoa2031994.
8. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021;384:497-511. doi: 10.1056/NEJMoa2023184.
9. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. *N*.

Engl. J. Med. 2021;384:643-649. doi: 10.1056/NEJMra2035343.

10. Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, Joo J, Kwak SH, Kim EO, Jung J, Kwon HS, Kim TB, Kim SH, Bae S. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea. J Korean Med Sci. 2021;36:e153. doi: 10.3346/jkms.2021.36.e153.
11. Nittner-Marszalska M, Rosiek-Biegus M, Kopeć A, Pawłowicz R, Kosińska M, Łata A, Szenborn L. Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals. Vaccines (Basel). 2021;9:553. doi: 10.3390/vaccines9060553.

Figure Legends

Figure 1. Frequency of adverse reactions after the first and second vaccinations. Adverse reactions other than pain at the injection site occurred more frequently after the second vaccination than after the first.

Figure 1

Table 1. Profile of subjects vaccinated with BNT162b2 mRNA COVID-19 vaccine

	First vaccination (1586)	Second vaccination (1306)
Male / Female	522 / 1064	388 / 918
Type of Job		
Doctor	320 (20.3%)	216 (16.6%)
Nurse	558 (35.3%)	509 (39.0%)
Technician	152 (9.6%)	123 (9.4%)
Clerk	371 (23.4%)	299 (22.9%)
Student	179 (11.3%)	157 (12.0%)
Unknown (no answer)	6 (3.8%)	2 (0.2%)
Age		
20-29	546 (34.4%)	427 (32.7%)
30-39	402 (25.3%)	321 (24.6%)
40-49	336 (21.2%)	288 (22.1%)
50-59	220 (13.9%)	197 (15.1%)
60-	82 (5.2%)	73 (5.6%)
History of allergy (food and/or medicine)	193 (12.2%)	160 (12.3%)
History of allergic diseases	698 (44.0%)	564 (43.2%)
History of anaphylaxis	27 (1.7%)	13 (1.0%)
History of adverse response to vaccination	90 (5.7%)	91 (7.0%)

Table 2. The onset of adverse reactions, duration of symptoms, and severity of symptoms after the first and second vaccination

		Number of cases (%)	Onset on the day of vaccination (%)	Continued for more than 2 days (%)	Moderate or severe symptoms (%)
Injection site pain	After first vaccination	1450 (91.4)	957 (60.3)	981 (61.9)	164 (10.3)
	After second vaccination	1193 (91.3)	807 (61.8)	896 (68.6)	437 (33.5)
Injection site swelling	After first vaccination	197 (12.4)	100 (6.3)	106 (6.7)	8 (0.5)
	After second vaccination	253 (19.4)	104 (8.0)	176 (13.5)	42 (3.2)
Fever (≥ 37.5 °C)	After first vaccination	68 (4.3)	18 (1.1)	16 (1.0)	23 (1.5)
	After second vaccination	583 (44.6)	134 (10.3)	185 (14.2)	322 (24.7)
Fatigue or malaise	After first vaccination	578 (36.4)	272 (17.2)	246 (15.5)	68 (4.3)
	After second vaccination	1043 (79.9)	315 (24.1)	573 (43.9)	561 (43.0)
Headache	After first vaccination	319 (20.1)	151 (9.5)	107 (6.7)	123 (7.8)
	After second vaccination	697 (53.4)	200 (15.3)	364 (27.9)	493 (37.7)
Chills	After first vaccination	115 (7.3)	52 (3.3)	30 (1.9)	28 (1.8)
	After second vaccination	634 (48.5)	224 (17.2)	219 (16.8)	375 (28.7)
Nausea	After first vaccination	63 (4.0)	42 (2.6)	14 (0.9)	10 (0.6)
	After second vaccination	128 (9.8)	41 (3.1)	43 (3.3)	35 (2.7)
Muscle pain outside the injection site	After first vaccination	389 (24.5)	210 (13.2)	262 (16.5)	56 (3.5)
	After second vaccination	462 (35.4)	179 (13.7)	278 (21.3)	198 (15.2)
Arthralgia	After first vaccination	116 (7.3)	44 (2.8)	50 (3.2)	16 (1.0)
	After second vaccination	469 (35.9)	107 (8.2)	221 (16.9)	264 (20.2)

Table 3. The frequency of adverse reactions by gender and age.

	Gender		p value	Age					p value
	Male	Female		20-29	30-39	40-49	50-59	60-	
First vaccination	522	1064		546	402	336	220	82	
Number	(%)	(%)		(%)	(%)	(%)	(%)	(%)	
Injection site pain	91.0	91.6	0.7028	92.1	96.0	90.8	85.0	84.2	<0.0001*
Injection site swelling	10.7	13.3	0.1685	15.8	9.5	10.4	11.8	14.6	0.0327*
Fever ($\geq 37.5^{\circ}\text{C}$)	4.4	4.2	0.8953	7.1	5.0	1.2	1.8	1.2	<0.0001*
Fatigue or malaise	30.1	39.6	0.0002*	38.3	37.3	33.9	37.7	26.8	0.2606
Headache	14.0	23.1	<0.0001*	22.2	23.1	16.7	16.8	14.6	0.0560
Chills	4.6	8.6	0.0038*	8.2	8.0	7.4	5.0	2.4	0.2314
Nausea	1.3	5.3	<0.0001*	6.0	3.5	2.4	2.7	2.4	0.0400*
Muscle pain outside the injection site	15.3	29.0	<0.0001*	24.9	21.9	23.5	30.0	24.4	0.2579
Arthralgia	5.8	8.1	0.1009	8.4	6.0	6.6	8.6	6.1	0.5408

Second vaccination	388	918		427	321	288	197	73	
Number	(%)	(%)		(%)	(%)	(%)	(%)	(%)	
Injection site pain	89.7	92.1	0.1958	93.9	94.4	91.0	83.8	84.9	<0.0001*
Injection site swelling	17.5	20.2	0.2844	21.6	17.8	17.4	19.8	20.6	0.6161
Fever ($\geq 37.5^{\circ}\text{C}$)	36.6	48.0	0.0002*	54.1	46.1	42.4	34.5	19.2	<0.0001*
Fatigue or malaise	71.4	83.4	<0.0001*	82.0	81.9	80.9	75.6	65.8	0.0093*
Headache	41.5	58.4	<0.0001*	60.2	56.7	48.6	45.7	38.4	0.0001*
Chills	37.6	53.2	<0.0001*	50.1	54.8	50.4	39.6	28.8	<0.0001*
Nausea	4.6	12.0	<0.0001*	12.7	8.1	8.7	10.7	2.7	0.0467*
Muscle pain outside the injection site	25.7	39.7	<0.0001*	37.7	33.0	32.6	42.1	24.7	0.0351*
Arthralgia	25.5	40.3	<0.0001*	37.0	38.6	34.4	37.1	20.6	0.0576

*: Significantly different between groups

Table 4. The frequency of adverse reactions by allergic status.

	History of allergies to food and/or medicine		p value	History of allergic diseases		p value	History of anaphylaxis		p value	history of adverse reactions after vaccination		p value
	No	Yes		No	Yes		No	Yes		No	Yes	
First vaccination	1393	193		888	698		1559	27		1496	90	
Number	(%)	(%)		(%)	(%)		(%)	(%)		(%)	(%)	
Injection site pain	91.4	91.7	1.0000	89.4	94.0	0.0015*	91.3	96.3	0.7236	91.1	96.7	0.0788
Injection site swelling	12.1	15.0	0.2446	10.7	14.6	0.0213*	12.5	7.4	0.5664	11.7	24.4	0.0014*
Fever (≥ 37.5 °C)	4.1	5.7	0.3401	3.4	5.4	0.0463*	4.2	11.1	0.1059	3.9	11.1	0.0039*
Fatigue or malaise	34.9	47.7	0.0008*	32.1	42.0	<0.0001*	36.1	55.6	0.0440*	35.7	48.9	0.0131*
Headache	18.8	29.5	0.0008*	17.3	23.6	0.0020*	20.2	14.8	0.6315	19.5	30.0	0.0209*
Chills	6.5	12.4	0.0069*	6.2	8.6	0.0788	7.1	14.8	0.1265	6.8	15.6	0.0050*
Nausea	3.4	8.3	0.0027*	2.7	5.6	0.0042*	4.0	3.7	1.0000	3.8	6.7	0.1659
Muscle pain outside the injection site	24.2	26.9	0.4219	24.4	24.6	0.9531	24.7	14.8	0.3652	24.7	21.1	0.5282
Arthralgia	6.7	11.9	0.0121*	5.7	9.3	0.0085*	7.4	3.7	0.7164	7.2	10.0	0.2972

Second vaccination	1146	160		742	564		1293	13		1215	91	
Number	(%)	(%)		(%)	(%)		(%)	(%)		(%)	(%)	
Injection site pain	90.9	94.4	0.1763	90.2	92.9	0.0911	91.3	100.0	0.6186	90.7	100.0	0.0003*
Injection site swelling	19.1	21.3	0.5224	17.1	22.3	0.0197*	19.5	7.7	0.4823	18.6	29.7	0.0131*
Fever (≥ 37.5 °C)	44.1	48.8	0.2709	44.5	44.9	0.9106	44.6	46.2	1.0000	44.4	48.4	0.5122
Fatigue or malaise	79.5	82.5	0.4017	78.3	81.9	0.1097	79.7	92.3	0.4848	79.3	86.8	0.1031
Headache	51.9	63.8	0.0052*	51.5	55.9	0.1306	53.7	23.1	0.0464*	52.9	59.3	0.2760
Chills	47.8	53.8	0.1768	48.1	49.1	0.7375	48.3	69.2	0.1670	48.2	53.9	0.3281
Nausea	8.6	18.8	0.0002*	8.0	12.2	0.0111*	9.9	0.0	0.6291	9.1	19.8	0.0027*
Muscle pain outside the injection site	34.2	43.8	0.0216*	35.4	35.3	1.0000	35.4	30.8	1.0000	34.9	41.8	0.2111
Arthralgia	34.5	46.3	0.0048*	35.7	36.2	0.9073	35.7	61.5	0.0777	35.1	46.2	0.0411*

*: Significantly different between groups

Table 5. The frequency of adverse reactions continued more than 2 days

	History of allergies to food and/or medicine			History of allergic diseases			History of anaphylaxis			history of adverse reactions after vaccination		
	No	Yes	p value	No	Yes	p value	No	Yes	p value	No	Yes	p value
First vaccination	Number	1393	193		888	698		1559	27		1496	90
	(%)	(%)		(%)	(%)		(%)	(%)		(%)	(%)	
Injection site pain	61.2	66.3	0.1209	59.3	65.0	0.3357	61.8	63.0	1.0000	61.2	72.2	0.1233
Injection site swelling	6.4	8.8	0.6888	6.1	7.4	0.4722	6.7	3.7	1.0000	6.3	13.3	1.0000
Fever (≥ 37.5 °C)	0.9	1.6	0.7120	0.3	1.9	0.0233*	1.0	0.0	1.0000	0.9	2.2	1.0000
Fatigue or malaise	14.3	24.4	0.0469*	12.7	19.1	0.1071	15.5	14.8	0.2884	15.0	24.4	0.3379
Headache	6.2	10.4	0.7579	5.3	8.6	0.2841	6.9	0.0	0.5536	6.5	11.1	0.6671
Chills	1.7	3.6	0.6053	1.4	2.6	0.3949	1.8	7.4	0.1688	1.7	5.6	0.3221
Nausea	0.7	2.1	0.7337	0.6	1.3	1.0000	0.9	0.0	1.0000	0.8	2.2	0.6167
Muscle pain outside the injection site	16.0	20.2	0.2573	16.6	16.5	0.8222	16.6	11.1	1.0000	16.5	16.7	0.4493
Arthralgia	2.7	6.7	0.1525	2.6	3.9	1.0000	3.1	3.7	0.4425	3.0	5.6	0.5058

Second vaccination	Number	1146	160		742	564		1293	13		1215	91
	(%)	(%)		(%)	(%)		(%)	(%)		(%)	(%)	
Injection site pain	67.6	75.6	0.1536	64.7	73.8	0.0021*	68.4	84.6	0.7451	67.6	82.4	0.1282
Injection site swelling	13.3	15.0	1.0000	11.1	16.7	0.0979	13.5	7.7	1.0000	12.7	24.2	0.2647
Fever (≥ 37.5 °C)	13.8	16.9	0.5152	12.8	16.0	0.1055	14.1	23.1	0.3900	13.8	18.7	0.3181
Fatigue or malaise	42.3	55.0	0.0049*	41.6	46.8	0.1664	43.7	61.5	0.5633	42.8	58.2	0.0336*
Headache	26.3	39.4	0.0403*	27.8	28.0	0.4439	27.9	23.1	0.2511	26.9	40.7	0.0159*
Chills	15.4	26.9	0.0021*	15.5	18.4	0.1533	16.6	30.8	0.5049	16.5	20.9	0.5342
Nausea	2.6	8.1	0.2699	2.7	4.1	1.0000	3.3	0.0	1.0000	3.1	5.5	0.7886
Muscle pain outside the injection site	20.0	30.6	0.0584	21.2	21.5	0.8456	21.3	23.1	1.0000	20.9	26.4	0.4702
Arthralgia	15.9	24.4	0.3757	15.8	18.4	0.1344	16.7	38.5	0.4876	16.4	24.2	0.4081

*: Significantly different between groups

Table 6. The frequency of moderate to severe reactions (for fever, body temperature of 38° C or higher, and for other adverse reactions, those that interfere with daily life or require medical treatment)

	History of allergies to food and/or medicine			History of allergic diseases			History of anaphylaxis			history of adverse reactions after vaccination			
	No	Yes	p value	No	Yes	p value	No	Yes	p value	No	Yes	p value	
First vaccination	Number	1393	193		888	698		1559	27		1496	90	
	(%)	(%)		(%)	(%)		(%)	(%)		(%)	(%)		
Injection site pain	9.8	14.0	0.0989	10.7	9.9	0.4050	10.3	11.1	1.0000	10.0	15.6	0.1618	
Injection site swelling	0.6	0.0	0.6093	0.7	0.3	0.1528	0.5	0.0	1.0000	0.4	2.2	0.2295	
Fever (>= 37.5 °C)	1.5	1.0	0.3101	1.4	1.6	0.4402	1.4	3.7	1.0000	1.3	4.4	0.7236	
Fatigue or malaise	3.7	8.3	0.0794	3.8	4.9	1.0000	4.2	7.4	0.6984	3.7	13.3	0.0031*	
Headache	7.2	11.9	1.0000	6.4	9.5	0.5648	7.9	0.0	0.0854	7.2	16.7	0.0659	
Chills	1.7	2.6	0.7921	1.2	2.4	0.3852	1.7	7.4	0.2487	1.6	4.4	0.7423	
Nausea	0.4	2.1	0.4358	0.5	0.9	1.0000	0.6	0.0	1.0000	0.6	1.1	1.0000	
Muscle pain outside the injection site	3.2	5.7	0.2035	4.1	2.9	0.2413	3.5	3.7	0.4900	3.6	2.2	1.0000	
Arthralgia	0.6	3.6	0.0165*	0.7	1.4	0.5994	1.0	3.7	0.1441	0.9	2.2	0.6151	
Second vaccination	Number	1146	160		742	564		1293	13		1215	91	
	(%)	(%)		(%)	(%)		(%)	(%)		(%)	(%)		
Injection site pain	33.1	36.3	0.6509	31.5	36.0	0.1825	33.3	53.8	0.2491	32.3	48.4	0.0232*	
Injection site swelling	3.1	3.8	0.8091	2.6	4.1	0.6125	3.2	7.7	0.1673	3.4	1.1	0.0579	
Fever (>= 37.5 °C)	24.6	25.0	0.4630	25.2	23.9	0.3996	24.7	15.4	0.4144	24.4	27.5	0.8762	
Fatigue or malaise	42.8	43.8	0.9251	42.7	43.3	0.5714	42.9	46.2	0.7788	42.2	52.7	0.2425	
Headache	36.6	46.3	0.4723	36.5	39.4	1.0000	38.0	15.4	1.0000	36.9	49.5	0.0583	
Chills	28.3	31.9	0.9051	29.2	28.0	0.4133	28.6	38.5	1.0000	27.7	41.8	0.0094*	
Nausea	2.3	5.6	0.8174	1.8	3.9	0.1699	2.7	0.0	1.0000	2.5	5.5	1.0000	
Muscle pain outside the injection site	14.0	23.8	0.0449*	14.6	16.0	0.3345	15.1	23.1	0.3303	14.7	20.9	0.2102	
Arthralgia	19.6	24.4	0.3701	20.9	19.3	0.2948	20.0	38.5	1.0000	19.8	25.3	0.7353	

*: Significantly different between groups